SOLUBLE ACE2, FUSED PROTEIN THEREOF AND METHODS OF USING THEM Russian patent published in 2025 - IPC C07K14/05 C12N9/48 A61P31/12 A61P31/14 

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology, namely to a fusion protein of soluble ACE2, which binds to a coronavirus, comprising a processed form of soluble ACE2, an Fc domain of an antibody and a tail, wherein the processed form of soluble ACE2 is bonded to the N-terminal region of the Fc-domain, and the tail is located on the C-terminal region of the Fc-domain, the processed form of soluble ACE2 contains or consists of the extracellular domain of ACE2 or a fragment of the extracellular domain of ACE2, which retains the ability to bind to the coronavirus, as well as to the Fc-fusion protein multimer, ACE2-hFc (n), which binds to a coronavirus comprising n polypeptide monomer units, and which is characterized in that each of the polypeptide monomer units is a dimer, in which two processed forms of soluble ACE2 are linked to N-terminal regions of two Fc-domains of heavy chains, respectively, and n polypeptide monomer units are assembled into a multimer by means of a tail located on each of C-ends of two Fc-domains of heavy chains, where n is selected from 4, 5 or 6. Also disclosed is a vector and a cell containing a gene coding said fused protein, and a cell and a vector containing a gene coding said multimer.

EFFECT: invention is effective in preparing a drug for treating or preventing a disease associated with ACE2.

17 cl, 16 dwg, 3 tbl, 12 ex